文献速递肝病

减重手术后代谢功能障碍相关脂肪性肝炎缓解且纤维化未恶化可改善15年生存:一项前瞻性队列研究

Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-19

该前瞻性队列研究纳入1994至2021年里尔大学医院3028例减重手术患者,评估基线及术后1年MASH和纤维化组织学进展与长期生存的关联。中位随访10.1年,基线MASH和F2-F4纤维化与15年生存缩短相关;1年时MASH缓解且纤维化未恶化者死亡率未增加。

要点

  • 基线MASH患者15年生存较无MASH者短(HR 2.21;95%CI 1.38-3.53)。
  • 基线F2-F4纤维化患者15年生存较F0-F1者短(HR 3.38;95%CI 2.24-5.10)。
  • 持续MASH和/或纤维化恶化者死亡率增加(aHR 2.54;95%CI 1.06-6.10),MASH缓解且纤维化未恶化者未增加(aHR 0.73;95%CI 0.28-1.87)。

核心结论

  • MASH或显著纤维化的组织学缓解可改善减重手术后的生存。

研究设计与样本

  • 前瞻性队列研究,1994至2021年里尔大学医院3028例减重手术患者,系统行基线肝活检并于术后1年建议随访活检。
  • 采用Cox回归模型评估基线及1年MASH和纤维化组织学进展与长期生存的关联。

主要发现

  • 基线2641例(89%)有肝活检,其中MASH 232例(8.7%),显著纤维化(F2-F4)266例(10.8%)。
  • 中位随访10.1年。
  • 15年随访时,基线MASH患者生存较无MASH者短(HR 2.21;95%CI 1.38-3.53),F2-F4患者生存较F0-F1者短(HR 3.38;95%CI 2.24-5.10)。
  • 1年标志分析:与无基线MASH者相比,持续MASH和/或纤维化恶化者死亡率增加(校正HR 2.54;95%CI 1.06-6.10),MASH缓解且纤维化未恶化者未增加(校正HR 0.73;95%CI 0.28-1.87)。
  • 与无基线显著纤维化者相比,持续显著纤维化者死亡率增加(校正HR 4.03;95%CI 1.86-8.72),纤维化从F2-F4改善至F0-F1者未增加(校正HR 1.49;95%CI 0.52-4.24)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The aim of this study was to investigate the consequences of the histological progression of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis on long-term survival after bariatric surgery. METHODS: From 1994 to 2021, 3028 patients at the University Hospital of Lille were prospectively included. Baseline liver biopsies were systematically performed with proposed follow-up biopsies 1 year after surgery, mainly in patients with MASH. We evaluated the association of the baseline and 1-year histologic progression of MASH and fibrosis status and long-term survival using Cox regression models. RESULTS: At baseline, 2641 patients (89%) had a biopsy, including 232 with MASH (8.7%) and 266 (10.8%) with significant fibrosis (grade F2-F4). The median follow-up was 10.1 years. At 1 year, 594 patients had qualitative paired biopsies. Survival was shorter at the 15-year follow-up in patients with baseline MASH, than in those without (hazard ratio [HR], 2.21; 95% confidence interval [CI], 1.38-3.53) and in F2 to F4 than in F0 to F1 (HR, 3.38; 95% CI, 2.24-5.10). At the 1-year landmark analysis, compared with patients without baseline MASH, mortality increased in those with persistent MASH and/or if fibrosis worsened (adjusted HR, 2.54; 95% CI, 1.06-6.10), but not if MASH resolved without the worsening of fibrosis (adjusted HR, 0.73; 95% CI, 0.28-1.87). Similarly, compared with patients without significant fibrosis at baseline, patients with persistent significant fibrosis had increased mortality (adjusted HR, 4.03; 95% CI, 1.86-8.72) but not if fibrosis improved from F2 to F4 to F0 to F1 (adjusted HR; 1.49; 95% CI, 0.52-4.24). CONCLUSION: Histologic remission of MASH or significant fibrosis improves survival after bariatric surgery.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lassailly G, Caiazzo R, Goemans A, et al. Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 39709138. doi:10.1016/j.cgh.2024.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。